Biliary stent with or without 125 I seeds for malignant obstructive jaundice : a systematic review and meta-analysis
Saimaiti Abuduwaili,L. Tao,Kahaer Tuerxun,Yu-Peng Li,Zhang Hao
2018-01-01
Abstract:Aim: The aim of this study was to assess the safety, feasibility, and efficacy of 125I seeds irradiation stents compared with conventional self-expandable metal stents (SEMS) to treat malignant obstructive jaundice (MOJ). Methods: A systematic search of English and Chinese databases, from January 1980 to June 2018, was conducted. All prospective random trials comparing SEMS and the various forms of irradiation stent with 125I seeds to treat MOJ were included. Results: Overall, Nine studies with 697 patients were eligible in the current analysis. Of reported 697 patients, 346 were subjected to irradiation stents and 353 to SEMS. The irradiation stents were associated with a longer survival (hazard ratio (HR) 0.50, IV, random, 95% confidence interval (CI) 0.37-0.67; P<0.001, I2=0%) and stent patency (HR 0.44, IV, random, 95% CI 0.33-0.60; P=0.27, I2=20%) than conventional SEMS. There were no differences in total complications rate (relative risk (RR) 0.95, M-H, random, 95% CI 0.65-1.37; P=0.77, I2=0%), hemobilia (RR 0.94, M-H, random, 95% CI 0.37-2.40; P=0.57, I2=0%), pain (RR 0.86, M-H, random, 95% CI 0.342.18; P=0.89, I2=0%), and cholangitis (RR 1.08, M-H, random, 95% CI 0.51-2.29; P=0.94, I2=0%). Also, no differences were observed in all indexes, which included total bilirubin (TBIL) (weighted mean difference (WMD) -7.18, IV, random, 95% CI -18.09-3.73; P=0.94, I2=23%), direct bilirubin (DBIL) (WMD -0.17, IV, random, 95% CI -10.81-10.46; P=0.49, I2=0%), alanine aminotransferase (ALT) (WMD -1.50, IV, random, 95% CI -12.52-9.52; P=0.01, I2=68%), aspartate aminotransferase (AST) (WMD 9.49, IV, random, 95% CI -9.31-28.29; P=0.21, I2=36%). Conclusions: The current meta-analysis suggest that the irradiation stent is a feasible, safe treatment of MOJ, with longer survival and stent patency. Application of an irradiation stent with anti-tumor effect do not add extra adverse events compared to SEMS stent.